智通财经APP获悉，近日，复星医药(02196)成功发行全国首单民营医药行业中长期科技创新债券，由招 商银行担任牵头主承销商兼簿记管理人，北京银行、浦发银行担任联席承销商，规模10亿元人民币，期 限2年，票面利率2.70%。 创立30多年来，复星医药始终以创新为核心发展驱动力，在创新药领域，自2019年以来，复星医药已累 计获批12款自主研发、许可引进的创新药和生物类似药，同时成功获得8款创新药物的中国境内商业化 权益，涵盖实体瘤、血液瘤、免疫炎症等核心治疗领域。2025年1月至5月，复星医药已有4款产品5项适 应症在中国及欧盟等多地获批，包括首个自研小分子创新药复迈宁®(芦沃美替尼片)获批上市，填补罕 见肿瘤领域空白；抗PD-1单抗斯鲁利单抗注射液成为欧盟首个获批用于广泛期小细胞肺癌(ES-SCLC)治 疗的PD-1单抗，国际化布局取得重要进展。 本期科创债获得了银行理财、保险、外资银行、公募基金、券商自营等各类型金融机构的踊跃认购，与 此同时，中债信用增进投资股份有限公司也积极参与本期债券的认购，代表监管部门为本期科创债发行 给予大力支持。本期债券募集资金将为复星医药在关键科技创新领域的布局提供有力的资金 ...

Core Viewpoint - The article highlights the rapid growth and transformation of China's innovative drug development sector, emphasizing its shift from quantity to quality and its increasing global competitiveness [2][8][20]. Summary by Sections Innovative Drug Approvals - In the first half of 2025, China approved 43 innovative drugs, a 59% increase year-on-year, nearing the total of 48 approvals in 2024 [2]. - The innovative drug sector is benefiting from favorable policies that support the entire industry chain, showcasing China's growing global competitiveness in biopharmaceuticals [2]. Clinical Development and Regulatory Efficiency - The average time for innovative drug approval has decreased from 420 working days in 2017 to 235 days [5]. - Measures have been implemented to improve access to rare disease medications, with several rare disease drugs approved in the first half of 2025 [5][7]. Shift in Drug Development Focus - Chinese innovative drug development is transitioning from "Me-too" drugs to "Best-in-class" drugs, with a focus on unmet clinical needs [8]. - The industry is enhancing its research capabilities and internationalization, with a notable increase in original innovations [8][20]. International Collaboration and Market Expansion - Chinese companies are exploring various models for international recognition, including licensing, joint development, and independent market entry [10][12]. - Notable collaborations include agreements between companies like 3SBio and Pfizer, and Heng Rui Pharma with GSK, aimed at accelerating drug development and market entry [11][12]. Global Registration and Recognition - Chinese innovative drugs are achieving global recognition, with products like Zepzelca and others gaining approval in major markets [16]. - Companies are focusing on high-quality clinical research and compliance with international standards to enhance their global competitiveness [18][19]. Challenges and Future Directions - Despite progress, challenges remain in areas such as platform technology accumulation and global commercialization experience [23]. - The industry needs to enhance its capabilities in original innovation and market access strategies to improve the commercialization of new drugs [23][24]. Policy Support and Industry Development - The government is actively supporting true innovation and differentiated innovation through various policies [21][24]. - Future industry development requires collaboration across multiple sectors, including regulatory improvements and talent development [24][25].

Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of injection Nadir platinum by the National Medical Products Administration [2][4]. Drug Information and Research Status - The drug is a self-developed chemical product by the group, intended for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, testicular cancer, ovarian cancer, and cervical cancer [3]. - As of July 2025, the cumulative R&D investment for this drug is approximately RMB 5.66 million (unaudited) [4]. - According to the latest IQVIA CHPA data, the projected sales for injection Nadir platinum in mainland China (excluding Hong Kong, Macau, and Taiwan) for 2024 is approximately RMB 353 million [4].

Core Viewpoint - Fosun Pharma's subsidiary, Gismed (Wuhan) Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the drug registration application of injectable Nedaplatin, which is a self-developed chemical drug intended for various cancers [1] Group 1 - The drug Nedaplatin is designed for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, testicular tumors, ovarian cancer, and cervical cancer [1]

Group 1 - The core point of the article is that Fosun Pharma announced the acceptance of its subsidiary's drug registration application for injection of Nedaplatin by the National Medical Products Administration [2] Group 2 - The announcement was made on the evening of August 12 [2] - The subsidiary involved is Gismed (Wuhan) Pharmaceutical Co., Ltd. [2] - The drug in question is Nedaplatin, which is used for injection [2]

Core Viewpoint - The company is focusing on divesting non-core businesses and optimizing its asset structure to enhance cash flow, with plans to recover over 2 billion RMB through asset disposals in 2024 [2]. Group 1: Non-Core Business Strategy - The company plans to exit non-core businesses, which will be determined by market conditions and business planning to ensure strategic focus and shareholder interests [2]. - The scale of the non-core investments and the timeline for exiting these investments have not been specified, indicating a flexible approach based on various factors [2]. Group 2: Strategic Investment - The strategic investment by Fosun Health in Foshan Zhanxi City Investment is still in progress, with both parties actively working on the implementation [2].

Core Viewpoint - Fosun Pharma's subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of injectable Nedaplatin by the National Medical Products Administration, indicating progress in the company's drug development pipeline [1]. Group 1 - The drug Nedaplatin is a self-developed chemical medication by the group [1]. - It is intended for the treatment of various cancers, including head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, testicular cancer, ovarian cancer, and cervical cancer [1].

Core Viewpoint - Fosun Pharma's subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the drug registration application of injectable Nedaplatin, which is a self-developed chemical drug intended for various cancers [1] Group 1 - The drug is designed for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, testicular tumors, ovarian cancer, and cervical cancer [1] - As of July 2025, the total R&D investment for this drug is approximately RMB 5.66 million (unaudited) [1]

Core Viewpoint - Fosun Pharma's subsidiary, Gismed (Wuhan) Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of injectable Nedaplatin from the National Medical Products Administration, indicating progress in the company's drug development pipeline [1] Group 1: Drug Development - The drug Nedaplatin is a self-developed chemical drug by the group, intended for the treatment of various cancers including head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, testicular tumor, ovarian cancer, and cervical cancer [1] - As of July 2025, the cumulative R&D investment for this drug is approximately RMB 5.66 million (unaudited) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司獲藥品註冊申請受理的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年8 月1 2 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 ...